Company news

Cheng Du Sheng Nuo Biotec Co., Ltd. Class A (SSE:688117) news

Cheng Du Sheng Nuo Biotec Co., Ltd. Class A news releases on 6ix. Latest, Sep 30, 2026: "CHENGDU SHENG NUO BIOTEC CO., LTD."Announcement on Voluntary…

Cheng Du Sheng Nuo Biotec Co., Ltd. Class A (SSE:688117) news

Press releases & updates

"CHENGDU SHENG NUO BIOTEC CO., LTD."Announcement on Voluntary Disclosure of Wholly-owned Subsidiary Obtaining the Drug Manufacturing License for New API Varieties and Passing the GMP Compliance Inspection

"CHENGDU SHENG NUO BIOTEC CO., LTD."Announcement on Progress of Shareholding Increase by Senior Management

"CHENGDU SHENG NUO BIOTEC CO., LTD."Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for Linaclotide Capsules

"CHENGDU SHENG NUO BIOTEC CO., LTD."Announcement on Voluntary Disclosure of the Receipt of the Approval Notice for the Marketing Application of Terlipressin Acetate API

"CHENGDU SHENG NUO BIOTEC CO., LTD."Semi-annual Report for 2026

"CHENGDU SHENG NUO BIOTEC CO., LTD."Announcement on Convening the 2026 Semi-annual Performance Briefing

"CHENGDU SHENG NUO BIOTEC CO., LTD."Announcement on the Initial Grant of Restricted Shares to Participants

"CHENGDU SHENG NUO BIOTEC CO., LTD."Announcement on the Results of Shareholding Increase by the Controlling Shareholder and the Change in Shareholder Equity Reaching the 1% Threshold

"CHENGDU SHENG NUO BIOTEC CO., LTD."Review Opinion and Statement on the Public Disclosure of the List of Participants for the Initial Grant under the Company's 2026 Restricted Share Incentive Plan Issued by the Remuneration and Appraisal Committee of the Board of Directors

"CHENGDU SHENG NUO BIOTEC CO., LTD."Announcement on Voluntary Disclosure of Semi-annual Performance Forecast for 2026

"CHENGDU SHENG NUO BIOTEC CO., LTD."Announcement on Reply to Letter of Supervision and Inquiry on Information Disclosure of 2025 Annual Report

"CHENGDU SHENG NUO BIOTEC CO., LTD."Announcement on Resolutions of the 3rd Meeting of the 5th Board of Directors

"CHENGDU SHENG NUO BIOTEC CO., LTD."Announcement on the Controlling Shareholder's Shareholding Increase Plan

Announcement on Voluntary Disclosure of Notice on Listing Application Approval for Peligacaran Drug Substance

Announcement on Voluntary Disclosure of Notice on Listing Application Approval for Oxytocin Drug Substance

Announcement on Share Increase Plan for Senior Management Members

Announcement on Implementation of Dividend Distribution for 2025

Announcement on Voluntary Disclosure of Completion of U.S. FDA Filing for Terlipressin Acetate Substance

Announcement on Resolutions of the 2025 Annual General Meeting

Announcement on Convening Performance Briefing for 2025 and Q1 2026

Announcement on Voluntary Disclosure of Completion of U.S. FDA Filing for Tirzepatide Drug Substance

Announcement on 2025 Profit Distribution and Capital Reserve Conversion to Share Capital Plan and Interim Dividend Plan for 2026

Announcement on Voluntary Disclosure of Obtaining Drug Production License by Wholly-owned Subsidiary

Announcement on Shareholding Reduction Result and Non-Execution of Shareholding Reduction by Some Directors and Senior Management Members

Announcement on Voluntary Disclosure of Notice on Listing Application Approval for Liraglutide Drug Substance

Announcement on Preliminary Earnings Estimate for 2025

Announcement on Voluntary Disclosure of Proposed Selection Results of Participating in National Organized Bulk Purchasing of Drugs for Successive Procurements

Earnings Preannouncement for 2025

Announcement on Progress in Major Daily Operation Contracts of Wholly-owned Subsidiary

Announcement on Completing Term Change and Election of Board of Directors and Appointing Senior Management Members and Securities Affairs Representative

Announcement on Shareholding Reduction Results for Shareholders Holding Over 5% Shares, Partial Directors and Senior Management Members

Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares to Below 5% and Reaching 1% Scale

Announcement on Voluntary Disclosure of Pentapeptide-18 Passing the New Cosmetic Ingredient Registration

Announcement on Election of Board of Directors at Expiry of Term of Office

Announcement on Shareholding Reduction Plan of Partial Directors and Senior Management Members

Announcement on Voluntary Disclosure of Notice on Listing Application Approval for Vepnadeptide Drug Substance

Announcement on Implementation of Interim Dividend Distribution for 2025

Announcement on Making Provisions for Asset Impairment for the First Three Quarters of 2025

Indicative Announcement on Shareholder Terminating Concerted Action Relationship and Equity Change Reaching 1% Scale

Announcement on Voluntary Disclosure of Earnings Preannouncement for the First Three Quarters of 2025

Indicative Announcement on Change in Equity of Shareholders with Over 5% Shares Reaching 1% Scale

Announcement on Shareholding Reduction Plan for Shareholders Holding Over 5% Shares, Partial Directors and Senior Management Members

Announcement on Convening the 2025 Semi-annual Performance Briefing

2025 Semi-annual Report

Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for Ganirelix Injection

Announcement on Voluntary Disclosure of Obtaining Drug Registration Certificate for Exenatide Injection

Announcement on Voluntary Disclosure of 2025 Semi-annual Earnings Preannouncement

Announcement on Implementation of Dividend Distribution for 2024

Announcement on Resolution of the 2024 Annual General Meeting

Report for Q1 2025